Literature DB >> 34994886

A Modified Billroth-II with Braun Anastomosis in Totally Laparoscopic Distal Gastrectomy: Initial Experience Compared with Roux-en-Y Anastomosis.

Abudushalamu Yalikun1,2, Batuer Aikemu1,2, Shuchun Li1,2, Tao Zhang1,2, Junjun Ma3,4, Minhua Zheng5,6, Lu Zang7,8.   

Abstract

BACKGROUND: This retrospective study aimed to compare the feasibility and effectiveness of a modified Billroth-II with Braun (B-II Braun) reconstruction and those of a Roux-en-Y (R-Y) reconstruction after laparoscopic distal gastrectomy.
METHODS: From January 2016 to December 2019, 247 patients underwent total laparoscopic distal gastrectomy (TLDG), with B-II Braun reconstruction for 145 patients and R-Y reconstruction for 102 patients. The patients' data were collected prospectively and reviewed retrospectively.
RESULTS: In this study, the median times of the operation were statistically shorter for B-II Braun than for R-Y (167 min [range, 110-331 min] vs 191 min [range, 123-384 min]; p = 0.001), including anastomotic times (33 min [range, 30-42 min] vs 42 min [range, 40-48 min]; p = 0.001). After a short-term follow-up period, endoscopy showed 31 cases of bile reflux (21.4%), 15 cases of grade 2 gastritis (10.3%), and 6 cases of grade 2 food residue (4.1%) in the B-II Braun group after 6 months. After 1 year, 10 patients (6.9%) had grade 2 gastritis and 2 patients (1.4%) had grade 3 gastritis. However, the remnant stomach of the two groups did not differ significantly in the rate of gastric residue (p = 0.112 after 6 months; p = 0.579 after 1 year, respectively), gastritis (p = 0.726 after 6 months; p = 0.261 after 1 year, respectively), or bile reflux (p = 0.262 after 6 months; p = 0.349 after 1 year, respectively).
CONCLUSIONS: For gastric cancer patients, TLDG with modified B-II Braun reconstruction could be technically feasible. It has an acceptable range of postoperative complications and is effective in preventing bile reflux into the gastric remnant.
© 2021. Society of Surgical Oncology.

Entities:  

Mesh:

Year:  2022        PMID: 34994886     DOI: 10.1245/s10434-021-11187-4

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  40 in total

1.  Effect of Laparoscopic vs Open Distal Gastrectomy on 3-Year Disease-Free Survival in Patients With Locally Advanced Gastric Cancer: The CLASS-01 Randomized Clinical Trial.

Authors:  Jiang Yu; Changming Huang; Yihong Sun; Xiangqian Su; Hui Cao; Jiankun Hu; Kuan Wang; Jian Suo; Kaixiong Tao; Xianli He; Hongbo Wei; Mingang Ying; Weiguo Hu; Xiaohui Du; Yanfeng Hu; Hao Liu; Chaohui Zheng; Ping Li; Jianwei Xie; Fenglin Liu; Ziyu Li; Gang Zhao; Kun Yang; Chunxiao Liu; Haojie Li; Pingyan Chen; Jiafu Ji; Guoxin Li
Journal:  JAMA       Date:  2019-05-28       Impact factor: 56.272

2.  Long-term results after surgery for gastric cancer with or without jejunal reservoir: results of surgery for gastric cancer in Kanta-Häme central hospital in two consecutive periods without or with jejunal pouch reconstruction in 1985-1998.

Authors:  Hannu Paimela; Saara Ketola; Mauri Iivonen; Timo Tomminen; Esa Könönen; Niku Oksala; Harri Mustonen
Journal:  Int J Gastrointest Cancer       Date:  2005

3.  A Multi-institutional, Prospective, Phase II Feasibility Study of Laparoscopy-Assisted Distal Gastrectomy with D2 Lymph Node Dissection for Locally Advanced Gastric Cancer (JLSSG0901).

Authors:  Noriyuki Inaki; Tsuyoshi Etoh; Tetsuji Ohyama; Kazuhisa Uchiyama; Natsuya Katada; Keisuke Koeda; Kazuhiro Yoshida; Akinori Takagane; Kazuyuki Kojima; Shinichi Sakuramoto; Norio Shiraishi; Seigo Kitano
Journal:  World J Surg       Date:  2015-11       Impact factor: 3.352

4.  Duodenogastric reflux after gastric surgery.

Authors:  J O Svensson
Journal:  Scand J Gastroenterol       Date:  1983-09       Impact factor: 2.423

5.  Short-term Outcomes of a Multicenter Randomized Controlled Trial Comparing Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy to Open Distal Gastrectomy for Locally Advanced Gastric Cancer (KLASS-02-RCT).

Authors:  Hyuk-Joon Lee; Woo Jin Hyung; Han-Kwang Yang; Sang Uk Han; Young-Kyu Park; Ji Yeong An; Wook Kim; Hyoung-Il Kim; Hyung-Ho Kim; Seung Wan Ryu; Hoon Hur; Seong-Ho Kong; Gyu Seok Cho; Jin-Jo Kim; Do Joong Park; Keun Won Ryu; Young Woo Kim; Jong Won Kim; Joo-Ho Lee; Min-Chan Kim
Journal:  Ann Surg       Date:  2019-12       Impact factor: 12.969

6.  Multi-institutional validation of the 8th AJCC TNM staging system for gastric cancer: Analysis of survival data from high-volume Eastern centers and the SEER database.

Authors:  Taeil Son; Jiyu Sun; Seohee Choi; Minah Cho; In Gyu Kwon; Hyoung-Il Kim; Jae-Ho Cheong; Seung Ho Choi; Sung Hoon Noh; Yanghee Woo; Yuman Fong; Sohee Park; Woo Jin Hyung
Journal:  J Surg Oncol       Date:  2019-07-23       Impact factor: 3.454

7.  Comparison Between Billroth-II with Braun and Roux-en-Y Reconstruction After Laparoscopic Distal Gastrectomy.

Authors:  Chang In Choi; Dong Hoon Baek; Si Hak Lee; Sun Hwi Hwang; Dae Hwan Kim; Kwang Ha Kim; Tae Yong Jeon; Dong Heon Kim
Journal:  J Gastrointest Surg       Date:  2016-04-11       Impact factor: 3.452

8.  Functional outcomes according to the size of the gastric remnant and the type of reconstruction following distal gastrectomy for gastric cancer: an investigation including total gastrectomy.

Authors:  Eiji Nomura; Sang-Woong Lee; Takaya Tokuhara; Toshikatsu Nitta; Masaru Kawai; Kazuhisa Uchiyama
Journal:  Jpn J Clin Oncol       Date:  2013-09-24       Impact factor: 3.019

9.  Endoscopic evaluation of the remnant stomach after gastrectomy: proposal for a new classification.

Authors:  Makoto Kubo; Mitsuru Sasako; Takuji Gotoda; Hiroyuki Ono; Mitsuhiro Fujishiro; Daizo Saito; Takeshi Sano; Hitoshi Katai
Journal:  Gastric Cancer       Date:  2002       Impact factor: 7.370

10.  Clinicopathological features and surgical treatment of gastric cancer in South Korea: the results of 2009 nationwide survey on surgically treated gastric cancer patients.

Authors:  Oh Jeong; Young-Kyu Park
Journal:  J Gastric Cancer       Date:  2011-06-30       Impact factor: 3.720

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.